less efficient amplification of a longer fragment(833 bp compared with 112 ¨C238 bp) from mtDNA sheared to an average size of 300¨C400 bp. However, the D loop exists as a stable triple-helical structure containing an RNA primer required for initiation of mtDNA replication (13), and we have found this region to be resistant to in vitro methylation by M.Sss1 cytosine methyltransferase. It is therefore possible that the kinetics of epigenetic modification in this region of the mitochondrial genome might be different from those in coding regions.
ÔÚD»·¶ÔÕÕÇøÓòÓÐÒ»¸öÃ÷ÏԽϵÍ5hmC¸»¼¯×î¿ÉÄÜ·´Ó¦mtDNA½Ï³¤Æ¬¶Î£¨833bpÏà±È½Ï112-238bp£©ÐÞ¼ôΪƽ¾ù³¤¶È300-400bpÀ©ÔöЧÂʽϵ͡£È»¶ø£¬D»·µÄ´æÔÚ×÷Ϊһ¸öÎȶ¨µÄÈýÂÝÐý½á¹¹°üÀ¨mtDNA¸´ÖÆÆðʼËùÐèÒªµÄÒ»¸öRNAÒýÎ13£©£¬ÎÒÃÇ·¢ÏÖÕâ¸öÇøÓò¶ÔÓÚͨ¹ýM.Sss1°ûà×़׻ù×ªÒÆÃ¸ÌåÍâ¼×»ù»¯ÊÇÓеֿ¹µÄ¡£Òò´Ë£¬ÏßÁ£Ìå»ùÒò×éµÄÕâ¸öÇøÓòµÄ±í¹ÛÐÞÊζ¯Á¦Ñ§¿ÉÄܲ»Í¬ÓÚ±àÂëÇøµÄ¶¯Á¦Ñ§¡£
The function of 5hmC in the nuclear genome is not yet clear. It has been proposed that 5hmC is an intermediate metabolite in active demethylation of the genome by repair enzymes (30), in passive demethylation as a result of lack of recognition by enzymes involved in maintenance methylation (31)¾äÐÍ, or that it alters local chromatin structure because 5hmC is not recognized by 5-methylcytosine-binding proteins (7). The role of 5hmC in the mitochondrial genome likely involves one or more of these processes. Although quantitative measurements of the relative abundance of 5hmC and 5mC can be achieved using methylated DNA immunoprecipitation (Me-DIP), 5hMe-DIP, HPLC, or enzymatic methods, mapping the location and distribution of 5hmC in either the nuclear or mitochondrial genome is not yet technically feasible, because this modified base is indistinguishable from 5mC by bisulfite modification (7).
ºË»ùÒò×éÖеÄ5hmCµÄ¹¦ÄÜ»¹Ã»ÓкÜÇå³þ¡£Ìá³ö5hmCÊÇͨ¹ýÐÞ¸´Ã¸¶Ô»ùÒò×éµÄÖ÷¶¯È¥¼×»ù»¯Ò»¸öÖмä´úлÎ30£©£¬ÔÚ±»¶¯È¥¼×»ù»¯ÖÐ×÷Ϊ¶àά³Ö¼×»ù»¯Ã¸È±·¦ÈÏʶµÄÒ»¸ö½á¹û£¨31£©£¬»òÕß5hmC¸Ä±äµ±µØÈ¾É«Ìå½á¹¹ÒòΪ5hmCÊÇ»¹Ã»ÓÐͨ¹ý5¼×»ù°ûà×ऽáºÏµ°°×ÈÏʶ£¨7£©¡£5hmCÔÚÏßÁ£Ìå»ùÒò×éÖеÄ×÷ÓúܿÉÄÜÉæ¼°ÕâЩ¹ý³ÌµÄÒ»¸ö»òÕß¶à¸ö¡£¾¡¹Ü5hmCºÍ5mCµÄÏà¶Ô·á¶¼µÄ¶¨Á¿²âÁ¿Äܹ»Í¨¹ýʹÓü׻ù»¯µÄDNAÃâÒß¹²³Áµí£¨Me-DIP£©£¬5hMe-DIP£¬HPLC£¬»òø´ß»¯µÄ·½·¨»ñµÃ£¬»æÖÆ5hmCÔÚϸ°ûºË»òÕßÏßÁ£Ìå»ùÒò×éÖеÄλÖúͷֲ¼»¹Ã»Óм¼ÊõÉϵĿÉÐÐÐÔ£¬ÒòΪÕâЩÐÞÊμî»ùͨ¹ýÑÇÁòËáÇâÑÎÓë5mC²»ÄÜÇø·ÖµÄ£¨7£©¡£
This study reports a mitochondrial isoform of DNA methyltransferase 1, which is the only member of the catalytically active mammalian DNA methyltransferase family found in this organelle. The conservation of an ORF encoding a mitochondrial targeting sequence upstream of the commonly accepted translational start codon across multiple mammalian species suggests an important role for this enzyme in mitochondrial function.
Õâ¸öÑо¿±¨µÀÒ»¸öÏßÁ£ÌåDNA¼×»ù×ªÒÆÃ¸1µÄÑÇÐÍ£¬ËüÊÇÔÚÕâ¸öϸ°ûÆ÷Öз¢ÏֵIJ¸È鶯ÎïDNA¼×»ù×ªÒÆÃ¸¼Ò×åΨһ¾ßÓд߻¯»îÐԵġ£±£ÊصÄÒ»¸ö¿ª·ÅÔĶÁ¿ò±àÂëµÄÒ»¸öÏßÁ£Ìå°ÐÐòÁÐÆÕ±é¹«ÈϵÄת¼ÆðʼÃÜÂë×ÓÉÏÓδ©¹ý¶àÖÖ²¸È鶯ÎïÎïÖÖÏÔʾÕâ¸öøÔÚÏßÁ£Ì幦ÄÜÖеÄÒ»¸öÖØÒª×÷Óá£
Although DNMT1 is generally considered to be £¨ÈÏΪÊÇ£©the maintenance DNA methyltransferase, it is able to methylate completely unmethylated DNA in vitro with an efficiency that exceeds that of the de novo methyltransferases DNMT3a and -3b (32). Thus,DNMT1 appears to be capable of both initiating and maintaining cytosine methylation in the nucleus, and the lack of de novo methyltransferases in mitochondria implicates mtDNMT1 in both processes in this organelle.
¾¡¹ÜDNMT1ÆÕ±é±»ÈÏΪÊÇά³ÖDNAµÄ¼×»ù×ªÒÆÃ¸£¬ËûÄÜÔÚÌåÍâ¼×»ù»¯Íêȫδ¼×»ù»¯µÄDNA
ЧÂʳ¬¹ýÁË´ÓÍ·¼×»ù×ªÒÆÃ¸DNMT3aºÍ-3bµÄЧÂÊ£¨32£©¡£Òò´Ë£¬DNMT1ËÆºõÔÚϸ°ûºËÖоßÓдÓÍ·ºÍά³Ö°ûà×़׻ù»¯Á½ÖÖÄÜÁ¦¡£ÏßÁ£ÌåÖÐȱ·¦´ÓÍ·¼×»ù×ªÒÆÃ¸°µÊ¾DNMT1ÔÚÕâ¸öϸ°ûÆ÷ÖоßÓÐÕâÁ½¸ö¹ý³Ì¡£
We show that mtDNMT1 binds to the mitochondrial genome in a manner£¨ÔÚijÖÖÒâÒåÉÏ£¬ÔÚijÖ̶ֳÈÉÏ£© proportional to the density of CpG dinucleotides. Of particular relevance is the binding of mtDNMT1 to the D-loop control region, which carries the promoters driving transcription initiation of both heavy and light strands, supporting a role for mtDNMT1 in regulation of mitochondrial gene expression. The asymmetric, gene-specific alteration in mitochondrial transcription patterns shown here suggests diverse roles for mtDNMT1 and cytosine modification in this organelle.
ÎÒÃÇÏÔʾmtDNMT1½áºÏÏßÁ£Ìå»ùÒò×éÔÚijÖ̶ֳÈÉÏÓëCpG¶þºËÜÕËáÃܶȳɱÈÀý¡£ÌرðÏà¹ØµÄÊÇmtDNMT1ÓëD»·¶ÔÕÕÇø½áºÏ£¬D»·¶ÔÕÕÇøÐ¯´øÇý¶¯ÖØÁ´ºÍÇáÁ´Á½Õßת¼ÆðʼµÄÆô¶¯×Ó£¬Ö§³ÖmtDNMT1ÔÚµ÷½ÚÏßÁ£Ìå»ùÒò±í´ïÖеŦÄÜ¡£²»¶Ô³ÆµØ£¬±¾ÎıíÃ÷ÔÚÏßÁ£Ìåת¼ģʽÖжÀÌØ»ùÒòµÄ¸Ä±ä£¬°µÊ¾ÔÚÕâ¸öϸ°ûÆ÷ÖÐmtDNMTºÍ°ûà×à¤ÐÞÊξßÓкܶà×÷Óá£
Decreased expression of ND6 on the L strand implies that cytosine methylation in mtDNA represses gene expression from the light-strand promoter, as it does in the nucleus. However, increased transcription of ND1 with no change in transcription of ATP6 or COX1 raises the possibility of a different mode of action on the H strand. A binding site for mitochondrial terminator factor 1 (MTERF1) is located between the end of the 16S rRNA gene and the translation start of ND1 (33). MTERF1 binds to both H-strand promoter 1(HSP1) and the terminator binding site (Fig.4A), forming a transcription loop that maintains high-level production of rRNA. Transcripts initiating at HSP2 produce polycistronic messages encoding the entire H strand (13).
LÁ´ND6±í´ï¼õÉÙ±íÃ÷mtDNA°ûà×़׻ù»¯ÒÖÖÆ´ÓÇáÁ´Æô¶¯×Ó¿ªÊ¼µÄ»ùÒò±í´ï£¬ºÍÔÚϸ°ûºËÖеÄÒ»Ñù¡£È»¶ø£¬ND1ת¼µÄÔö¼ÓûÓиıäATP6ºÍCOX1µÄת¼Ôö¼ÓÖØÁ´Éϲ»Í¬×÷ÓÃģʽµÄ¿ÉÄÜÐÔ¡£ÏßÁ£ÌåÖÕÖ¹×ÓÒò×Ó£¨MTERF1£©½áºÏλµãλÓÚ16S rRNA»ùÒòĩβºÍND1ת¼Æðʼ֮¼ä£¨33£©¡£MTERF1½áºÏµ½HÁ´Æô¶¯×Ó1£¨HSP1£©ºÍÖÕÖ¹×Ó½áºÏλµãÉÏ£¨Fig.4A£©£¬ÐγÉÒ»¸öת¼»·£¬Ëüά³ÖrRNA¸ßˮƽ²úÎï¡£ÔÚHSP2ת¼Æðʼ²úÉú¶à˳·´×ÓµÄÐÅÏ¢±àÂëÕû¸öHÁ´£¨13£©¡£
Our data raise the possibility that mtDNMT1, either through modification of CpG dinucleotides or by direct protein¨Cprotein interaction, interferes with MTERF-dependent transcription termination, allowing read-through from HSP1 to the next transcriptional unit (ND1) without impacting polycistronic mRNA synthesis from HSP2. ÎÒÃǵÄÊý¾ÝÌá¸ßÁËmtDNMT1µÄ¿ÉÄÜÐÔ£¬²»¹ÜÊÇͨ¹ýCpG¶þºËÜÕËáµÄÐÞÊλ¹ÊÇͨ¹ýµ°°×ºÍµ°°×ÖʼäµÄÖ±½ÓÏ໥×÷Óã¬×è°ÁËÒÀÀµMTERFת¼µÄÖÕÖ¹£¬ÔÊÐí´ÓHSP1µ½ÏÂÒ»¸öת¼µ¥Ôª£¨ND1£©µÄͨ¶Á²»Ó°Ïì´ÓHSP2¶à˳·´×ÓµÄmRNAºÏ³É¡£
We show here that DNMT1 is present in the mitochondrial matrix, bound to mtDNA, and modifies transcription of the mitochondrial genome in what appears to be a gene-specific fashion. We report the presence of both 5hmC and 5mC in mtDNA , suggesting that earlier studies may have underestimated the proportion of modified cytosines in this genome. Hence,mtDNMT1 appears to be responsible for£¨ÊÇ¡£¡£µÄÔÒò£© the establishment and maintenance of cytosine methylation in mtDNA, from which 5hmC is presumably derived. Our data support a role for epigenetic modification of the mitochondrial genome in regulation of mitochondrial transcription.
ÕâÀïÎÒÃDZíÃ÷DNMT1´æÔÚÓÚÏßÁ£Ìå»ùÖÊÖУ¬½áºÏmtDNA£¬ÐÞÊÎÏßÁ£Ìå»ùÒò×éµÄת¼£¬Õâ¸öËÆºõ¶ÀÌØµÄ»ùÒò·½Ê½ÊÇʲô¡£ÎÒÃDZ¨µÀÁËmtDNAÖдæÔÚ5mCºÍ5hmC£¬±íÃ÷֮ǰµÄÑо¿ºÜ¿ÉÄܵ͹ÀÁ˰ûà×à¤ÐÞÊÎÔÚÕâ»ùÒò×éÖеıÈÀý¡£Òò´Ë£¬mtDNMT1ËÆºõÊÇÔÚmtDNAÖн¨Á¢ºÍά³Ö°ûà×़׻ù»¯µÄÔÒò£¬ÕâºÜ¿ÉÄÜÊÇÓÉ5hmCÑÜÉúÀ´µÄ¡£ÎÒÃǵÄÊý¾ÝÖ§³ÖÁËÏßÁ£Ìå»ùÒò×éµÄ±í¹ÛÐÞÊÎÔÚµ÷½ÚÏßÁ£Ìåת¼ÖеÄ×÷ÓᣠMaterials and Methods ²ÄÁϺͷ½·¨
Cell Lines. HCT116 p53+/+ and HCT116 p53?/?were obtained from Bert Vogelstein, Johns Hopkins University (Balti more, MD). Primary MEFs were prepared from E12.5 ¨CE13.5 embryos. ϸ°ûϵ¡£HCT116 p53+/+ºÍP53?/? ´ÓJohns Hopkins University´óѧµÄBert Vogelstein²©Ê¿»ñµÃ(Balti more, MD)¡£Ö÷ÒªµÄMEFsϸ°ûÀ´×ÔE12.5-E13.5ÅßÌ¥¡£
Plasmids and Transfections. Primers used are listed in Table S2. Mitochondrial targeting sequences were amplified from random-primed human and mouse cDNAs. Murine NRF1 cDNA was obtained from the American Type Culture Collection and recloned into pDEST26/C-FLAG. PGC1¦Á plasmid was a gift from Gregorio Gil, Virginia Commonwealth University. Cells were transfected using Polyjet liposomes (ProSci) (HCT116) or nucleofection (Amaxa) (MEF and NIH/3T3) according to the manufacturers¡¯ specifications, and were harvested 48h after transfection.
ÖÊÁ£ºÍתȾ¡£Ê¹ÓñíS2ÖÐÁоٵÄÒýÎʹÓÃËæ»úÒýÎïÀ©ÔöСÊóºÍÈËÀàcDNAsÏßÁ£ÌåÄ¿±êÐòÁС£Ð¡ÊóNRF1 cDNA»ñµÃÓÚÃÀ¹ú±ê×¼¾ú¿âÈ»ºóÖØÐ¿Ë¡µ½pDEST26/C-FLAG¡£PGC1¦ÁÖÊÁ£ÓÉ Virginia Commonwealth University´óѧµÄGregorio GilÀ¡Ôù¡£Ê¹ÓÃPolyjet Ö¬ÖÊÌå(ProSci) (HCT116) »òºËתȾ(Amaxa) (MEF and NIH/3T3)°´ÕÕÖÆÔìÉÌ˵Ã÷ÊéתȾϸ°û£¬×ªÈ¾48hºóÊÕ»ñ¡£ Mitochondrial Purification and Immunoblot Analysis . Mitochondria were purified by dounce homogenization and differential centrifugation in the presence of complete protease inhibitors (Roche) (34). Proteins were resolved on 4 ¨C 15% gradient SDS/PAGE gels. Antibodies used were anti-DNM T1 amino acids 1¨C10 (Abcam), anti-tubulin and anti ¨Cvoltage-dependent anion carrier (VDAC) (Pierce), anti-H3K4me3 (Upstate Biotechnology), anti-DNMT3a and anti-DNMT3b (Imgenex), anti-GFP (Invitrogen), and anti-TAP (Open Biosystems). Protein was loaded onto SDS/PAGE gels to approximate equal cell equivalents, so that an equal signal for each compartment-specific antibody was obtained (whole-cell lysate, 75¦Ìg; cytosol, 25¦Ìg; mitochondria, 18¦Ìg).
ÏßÁ£Ìå´¿»¯ºÍÃâÒßÓ¡¼£·ÖÎö¡£Í¨¹ýdounce¾ùÖÊ»¯ºÍ²îËÙÀëÐÄÔÚÍêÕûµÄµ°°×øÒÖÖÆ¼Á£¨Roche£©´æÔÚʱ´¿»¯ÏßÁ£Ì壨34£©¡£µ°°×ÔÚ4-15%ÌݶÈSDS/PAGEÄý½º·ÖÀë¡£¿¹ÌåÓõÄÊÇ¿¹DNMT1°±»ùËá1-10£¨Abcam£©£¬¿¹Î¢¹Üµ°°×ºÍ¿¹µçѹÒÀÀµÐÔÒõÀë×ÓÔØÌ壨VDAC£©£¨Pierce£©£¬¿¹H3K4me3£¨Upstate Biotechnology£©£¬¿¹DNMT3aºÍ¿¹DNMT3b£¨Imgenex£©£¬¿¹GFP£¨Invitrogen£©£¬ºÍ¿¹TAP£¨Open Biosystems£©¡£ÏòSDS/PAGEÄý½ºÉÏÑù´óÖÂÏàµÈµÄϸ°ûµÈÁ¿µ°°×£¬ÒÔ±ã»ñµÃÌØ¶¨·Ö¸ô¿¹ÌåµÄÒ»¸öÏàµÈµÄÐźţ¨whole-cell lysate, 75¦Ìg; cytosol, 25¦Ìg; mitochondria, 18¦Ìg£©¡£ Confocal Microscopy. NIH/3T3 cells were plated onto poly-L-lysine-coated coverslips and fixed with 4% paraformaldehyde 48h after transfection . Cells were stained with 1nM MitoTracker Red (Molecular Probes) for 15 min washed three times with PBS, and mounted onto glass slides with ProLong Gold antifade reagent with DAPI (Invitrogen). Microscopy was carried out using a Leica TCS-SP2 AOBS confocal scanning microscope.
¹²¾Û½¹ÏÔ΢¾µ¡£×ªÈ¾48hºóµÄNIH/3T3ϸ°û½ÓÖÖµ½Í¿Óжà¾ÛLÀµ°±ËáµÄ²£Æ¬ÉÏ£¬ÓÃ4%¶à¾Û¼×È©¹Ì¶¨¡£Ï¸°ûÓÃ1nM MitoTracker Red (Molecular Probes)Ⱦɫ15minºóÓÃPBSÏ´3±é£¬È»
ºóÓÃDAIP ProLong Gold antifade reagent°²×°ÔÚÔØ²£Æ¬ÉÏ£¨Invitrogen£©¡£ÏÔ΢¾µ¼ì²éʹÓÃLeica TCS-SP2 AOBS ¹²¾Û½¹ÏÔ΢¾µ¡£
Gene Expression. Total RNA was isolated using TRIzol (Invitrogen), DNase I-treated, and reverse-transcribed with SuperScript III (Invitrogen ) and random hexamers. Gene expression was determined using qPCR with Quantitect SYBR Green PCR Mastermix (Qiagen). Values were normalized to 18S rRNA for mitochondrial transcription or to ¦Â-actin for mtDNMT1 quantitation. »ùÒò±í´ï¡£ÓÃTRLzoL£¨Invitrogen£©ÌáÈ¡×ÜRNA£¬DNase¢ñ´¦Àí£¬ÓÃSuperScript III £¨Invitrogen£©·´×ªÂ¼ºÍËæ»úÒýÎï¡£Quantitect SYBR Green PCR Mastermix £¨Qiagen£©½øÐÐqPCR¼ì²â»ùÒòµÄ±í´ï¡£ÏßÁ£Ìåת¼µÄÖµ±»18SrRNA±ê×¼»¯»òmtDNMT1¶¨Á¿±»¦Â-actin±ê×¼»¯¡£
Statistics. Statistical analyses of differential mitochondrial gene expression profiles were performed using a random-effects ANOVAËæ»ú·½²î·ÖÎö using the statistical package JMP version 7.0 (SAS). The least-squares mean for each gene for WT and p53?/ ?MEFs was obtained along with standard errors, and each dataset was normalized to 18S rRNA expression. Three independent sets of biological samples were analyzed for each gene, with triplicate technical replicates in each sample. The ANOVA model included technical replicates as nested effects and biological replicates as random effects. The corresponding 95% confidence intervals (C.I.) were obtained using statistical methods for transformations(Delta method). All other qPCR experiments include multiple replicates from two or more independent experiments, normalized to relevant controls or to input DNA. SDs were computed using the formulation.
ͳ¼Æ·ÖÎö¡£²»Í¬ÏßÁ£Ìå»ùÒò±í´ïͼÆ×µÄÊý¾Ý·ÖÎöÓÃJMP version 7.0 (SAS)ͳ¼ÆÈí¼þ°ü½øÐÐËæ»ú·½²î·ÖÎö¡£WTºÍ p53?/ ?MEFsϸ°ûÿ¸ö»ùÒòµÄ×îС¶þ³Ë·¨°éËæ×űê×¼Îó²î»ñµÃ£¬Ã¿¸öÊý¾Ý°´ÕÕ18SrRNA±í´ï½øÐбê×¼»¯¡£Èý¸ö¶ÀÁ¢ÉúÎïÑù±¾¼¯½øÐÐÿ¸ö»ùÒòµÄ·ÖÎö£¬Ã¿¸öÑù±¾½øÐÐÈý¸ö¼¼ÊõÖØ¸´¡£·½²î·ÖÎöģʽ°üÀ¨¼¼ÊõÖØ¸´×÷ΪǶÌ×ãкÍËæ»úÉúÎïÑ§ÖØ¸´¡£ÓÃת»»(Delta method)ͳ¼ÆÑ§·½·¨»ñµÃÏ൱ÓÚ95%¿ÉÐÅÇø¼ä£¨C.I.£©¡£ËùÓÐÆäËûµÄqPCRʵÑé°üÀ¨2µ½¸ü¶à¸ö¶ÀÁ¢ÊµÑéµÄ¶à¸öÖØ¸´£¬°´ÕÕÏà¹Ø¶ÔÕÕ»òÊäÈëµÄDNA½øÐбê×¼»¯¡£SDsÊÇÓÃÏÂÃæ¹«Ê½¼ÆËãµÄ¡£ Mitochondrial Immunoprecipitation. Purified mitochondria from DNMT1-TAP and nontagged HCT116 cells were formaldehyde-cross-linked, lysed, and immunoprecipitated as described (35). Mitochondrial DNA was sheared using a Diagenode Bioruptor water bath sonicator to an average length of 400bp.We used 750¦Ìg mitochondrial extract in each mitochondrial immunoprecipitation (mtIP) . IgG beads were equilibrated in lysis buffer and added to mitochondrial lysates for overnight incubation at 4¡ãC to isolate DNMT1-TAP/DNA complexes. ÏßÁ£ÌåÃâÒß¹²³Áµí¡£DNMT1-TAPºÍûÓбêÇ©HCT116ϸ°ûÖд¿»¯µÄÏßÁ£Ìå±»¼×È©½»Áª£¬Ï¸°ûÈܽâºÍ°´ÕÕÎÄÏ×ÖÐÃâÒß¹²³Áµí£¨35£©¡£ÏßÁ£ÌåDNAÓà Diagenode Bioruptorˮԡ³¬Òô²¨ÑùÆ·ÕðËéÒÇÐÞ¼ôΪƽ¾ù³¤¶ÈΪ400bpµÄƬ¶Î¡£Ã¿¸öÏßÁ£ÌåÃâÒß¹²³ÁµíÖУ¨mtIP£©ÎÒÃÇʹÓÃ750ugµÄÏßÁ£ÌåÌáÈ¡Îï¡£IgGСÖé×ÓÆ½ºâµ½Ï¸°ûÈܽâbufferÖУ¬¼ÓÈëÏßÁ£ÌåÈܽâ²úÎï4¡æ·õÓý¹ýÒ¹·ÖÀëDNMT1-TAP/DNA¸´ºÏÎï¡£
Immunoprecipitated samples were processed as described (35) and purified DNA was analyzed by qPCR with 1¦ÌL mtIP DNA and Quantitect SYBR Green Mastermix. The a bundance of mtDNA was determined from a standard curve of purified mtDNA and is expressed as ng mtDNA immunoprecipitated. Values obtained for non-TAP-tagged HCT116 cells represent nonspecific
background. Primers used were from Lu et al. (35)(fragments of 800 ¨C 900 bp, primers 1, 2, 3, and 27) or as listed in Table S2(fragments < 200bp). ÃâÒß¹²³ÁµíÑù±¾°´ÕÕÎÄÏ×ÖÐÒ»Ñù´¦Àí£¨35£©£¬ÓÃ1¦ÌL mtIP DNA ºÍQuantitect SYBR Green Mastermix¶Ô´¿»¯µÄDNA½øÐÐqPCR·ÖÎö¡£mt DNAµÄ·á¶Èͨ¹ý´¿»¯mtDNAµÄÒ»¸ö±ê×¼ÇúÏßÈ·¶¨£¬mtDNAÃâÒß¹²³ÁµíÓÃng±íʾ¡£non-TAP-tagged HCT116 cells´ú±í·ÇÌØÒìÐÔ±³¾°»ñµÃÖµ¡£ÒýÎïʹÓÃLu et al. (35)(fragments of 800 ¨C 900 bp, primers 1, 2, 3, and 27) or as listed in Table S2(fragments < 200bp)¡£
Mitochondrial 5mC and 5hmC Immunoprecipitation. Purified mtDNA (4 ¦Ìg) was sheared to an average length of 400bp and rotated overnight at 4¡ãC with 2ug IgG, anti-5mC, or anti-5hmC (Active Motif). The specificity of both antibodies for their respective cytosine modifications in DNA was verified using defined DNA substrates synthesized in the presence of dCTP, 5m-dCTP, or 5hm-dCTP (Active Motif). Precleared protein-G beads (Amersham) were used as previously described (23) to immunoprecipitate the antibody/DNA complexes, and DNA was purified from immunoprecipitates using proteinase K,organic extraction, and precipitation(23). The abundance of mtDNA was determined from a standard curve of purified mtDNA and is expressed as ng mtDNA immunoprecipitated relative to input values.
ÏßÁ£Ìå5mCºÍ5hmCÃâÒß¹²³Áµí¡£´¿»¯µÄmtDNA£¨4ug£©±»ÐÞ¼ôΪƽ¾ù³¤¶È400bpÓë2ug IgG£¬¿¹5mC»ò¿¹5hmC£¨Active Motif£©4¡æÐýת¹ýÒ¹¡£Ê¹ÓÃÒѾȷ¶¨µÄDNAÎïÖÊdCTP, 5m-dCTP, »ò5hm-dCTP (Active Motif)ºÏ³É£¬½øÐÐÖ¤Ã÷Á½¸ö¿¹Ìå¶ÔDNAÖÐËûÃǸ÷×Եİûà×à¤ÐÞÊÎÊÇÌØÒìÐԵġ£ÒѾ֤Ã÷µ°°×GСÖé×Ó(Amersham)ʹÓð´ÕÕ֮ǰ¿¹Ìå/DNA¸´ºÏÎïÃâÒß¹²³ÁµíµÄÃèÊö£¨23£©½øÐУ¬Ê¹Óõ°°×øK£¬ÓлúÝÍÈ¡ºÍ³ÁµíµÄ·½·¨´ÓÃâÒß¹²³ÁµíÖд¿»¯DNA£¨23£©¡£´ÓÒ»¸ö´¿»¯µÄmtDNA±ê×¼ÇúÏßÖÐÈ·¶¨mtDNA·á¶È£¬ÓÃng±íʾmtDNAÃâÒß¹²³ÁµíÏà¶ÔÓÚÊäÈëµÄÖµ¡£ Sequence-Specific Detection of 5hmC.The presence of 5hmC at Gla1 restriction sites was determined using a Quest 5hmC Detection Kit (Zymo Research) as described by the manufacturer using 80ng mtDNA or total cellular DNA. Gla1 cleaves DNA only when restriction-site cytosines are methylated or hydroxymethylated; glucosylation of 5hmC residues results in protection from Gla1 cleavage. Control DNAs used to validate the assay were from Active Motif.
5hmÌØÒâÐòÁеļì²â¡£5hmCÔÚGla1ÏÞÖÆÐÔλµãÉϵĴæÔÚÊÇQuest 5hmC Detection Kit (Zymo Research)È·¶¨µÄ£¬ÓÃ80ng mtDNA»ò×Üϸ°ûDNA°´ÕÕ˵Ã÷Êé²Ù×÷¡£Gla1·Ö¸îDNA½öµ±ÏÞÖÆÐÔλµã°ûà×à¤ÊǼ׻ù»¯»òÕßôǼ׻ù»¯Ê±£»ÆÏÌÇ»ù»¯5hmC²Ð»ùµ¼ÖÂGla1²»±»·Ö¸î¡£Ê¹ÓöÔÕÕDNAsȥ֤ʵÊÔ¼ÁºÐµÄ¼ì²â¡£
Ïà¹ØÍÆ¼ö£º